Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, in which the blocking receptor provides a signal that dominates a signal from the activating receptor.
Abstract: This document provides methods and materials for treating cancer. For example, foamy viruses (e.g., simian foamy viruses) are provided as well as methods and materials for treating cancer using foamy viruses as an oncolytic agent.
Type:
Grant
Filed:
April 12, 2019
Date of Patent:
January 21, 2025
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Yasuhiro Ikeda, Karol M. Budzik, Stephen James Russell
Abstract: Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization.
Type:
Grant
Filed:
June 23, 2022
Date of Patent:
January 21, 2025
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Stephen F. Badylak, Julie Anne Phillippi, Thomas G. Gleason, George R. Fercana, Jr.
Abstract: According to the present disclosure, there is provided a method for culturing cells into which a reprogramming factor is introduced including culturing cells into which a reprogramming factor is introduced; and recovering all cells into which the reprogramming factor is introduced and seeding and passaging at least part of the recovered cells in a medium. In addition, there is provided a method for culturing cells into which a reprogramming factor is introduced, including culturing cells into which a reprogramming factor is introduced; and inducing somatic cells different from pluripotent stem cells without passaging the cells into which the reprogramming factor is introduced.
Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
Type:
Grant
Filed:
April 13, 2022
Date of Patent:
January 7, 2025
Assignees:
Tigenix, S.A.U., Consejo Superior de Investigaciones Cientificas
Inventors:
Dirk Büscher, Manuel Angel González de la Peña, Mario Delgado Mora
Abstract: The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
December 17, 2024
Assignee:
UNIVERSITY OF MIAMI
Inventors:
Joshua M. Hare, Konstantinos Chatzistergos
Abstract: A method for culturing heart tissue by culturing a slice of the heart tissue in a culture medium, wherein the culture medium comprises fetal bovine serum (FBS), vascular endothelial cell growth factor (VEGF), and fibroblast growth factor (FGF); and applying electrical stimulation to the slice while the heart slice is in culture is provided. Methods of screening candidate therapeutic agents for therapeutic effect or cardiotoxicity using the culture system are also provided.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
December 17, 2024
Assignee:
University of Louisville Research Foundation
Abstract: The present disclosure provides improved humanized IgG1 FCRN mouse models for use, for example, in estimating serum half-life of therapeutic proteins such as monoclonal antibodies.
Type:
Grant
Filed:
February 25, 2022
Date of Patent:
December 3, 2024
Assignee:
The Jackson Laboratory
Inventors:
Michael V. Wiles, Derry C. Roopenian, Greg Christianson, Benjamin E. Low
Abstract: A fetal stem cell-derived extracellular vesicle has immune tolerance properties. The extracellular vesicle containing a fetal stem cell-derived primal immunoglobulin contains various natural antibodies and complement proteins which can immediately respond to foreign infectious agents such as viruses, bacteria, pathogens, etc., and thus can effectively treat and prevent infectious diseases through an enhanced innate immune system. Methods are disclosed for preparing the fetal stem cell-derived extracellular vesicle.
Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).
Type:
Grant
Filed:
July 2, 2018
Date of Patent:
November 19, 2024
Assignee:
CELLECTIS
Inventors:
David Sourdive, Aymeric Duclert, Mathieu Simon, Philippe Duchateau, Alan Marc Williams, Laurent Poirot
Abstract: Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative disease.
Type:
Grant
Filed:
April 23, 2021
Date of Patent:
November 12, 2024
Assignees:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., ARUNA BIO, INC.
Inventors:
Steven L. Stice, Robin Lynn Webb, Tracey A. Stice
Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
October 1, 2024
Assignee:
INSMED INCORPORATED
Inventors:
Karl E. Griswold, Chris Bailey-Kellogg, Yoonjoo Choi, Kristina Blazanovic, Hongliang Zhao, Deeptak Verma
Abstract: The invention relates to the use of germ cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.
Abstract: A blood storage system comprising: a collection vessel for red blood cells; an oxygen or oxygen and carbon dioxide depletion device; a storage vessel for red blood cells; tubing connecting the collection vessel to the oxygen or oxygen and carbon dioxide depletion device and the oxygen or oxygen and carbon dioxide depletion device to the storage vessel; and a gamma or X-ray irradiating device is used to irradiate red blood cells stored in the vessel, storing red blood cells under anaerobic conditions.
Abstract: A method is provided for preparing pericardial tissue that is used for a bioprosthetic heart valve assembly. According to this method, pericardial tissue is harvested from a host animal and then cleaned. The cleaned tissue is then fixed using glutaraldehyde. After fixation of the tissue, the residual antigenic components are removed to preserve the tissue structural integrity for its long-term performance. In addition, higher concentrations of alcohol are used to reduce the tissue bioburden, and at the same time to dehydrate the tissue followed by preserving the tissue with glycerol so as to mitigate glutaraldehyde-storage related issues for the bioprosthetic heart valve.
Abstract: Provided herein are methods of producing an RPE cell population from a starting cell suspension, such as a single cell suspension, of pluripotent stem cells (PSCs). Such a method may comprise culturing the starting single cell suspension of PSCs in differentiation media to produce human RPE cells.
Type:
Grant
Filed:
July 16, 2020
Date of Patent:
August 20, 2024
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, FUJIFILM Cellular Dynamics, Inc.
Inventors:
Kapil Bharti, Lucas Chase, Feng Xuezhu, Balendu Shekhar Jha
Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
Abstract: The disclosure is directed to methods for mobilizing hematopoietic stem cells (HSCs) and/or hematopoietic progenitor cells (HPCs) in a subject using sildenafil citrate and AMD3100.
Type:
Grant
Filed:
October 7, 2020
Date of Patent:
August 13, 2024
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention provides pharmaceutical compositions comprising a mesenchymal stromal cell (MSC) population, extracellular vesicles secreted from said MSC population, and a combination thereof, and methods of use thereof in treatment of a disease or disorder.